CoTherix, Quadrant to Develop Extended-Release Formulation of Ventavis

CoTherix has announced a collaborative research and development agreement with Quadrant Drug Delivery to develop an extended-release formulation of CoTherix's product, Ventavis inhalation solution.

The goal of this initiative is to reduce the frequency and duration of dosing. Financial terms of the agreement were not disclosed. Ventavis (iloprost) is marketed by CoTherix in the U.S. for the treatment of pulmonary arterial hypertension (World Health Organization Group I) in patients with NYHA Class III or IV symptoms.